MaxCyte Inc
MXCT1.520USD
-0.100-6.17%
Fechamento 09/19, 16:00（ET）Cotações atrasadas em 15 min
162.02MValor de mercado
PerdaP/L TTM
Mais detalhes de MaxCyte Inc Empresa
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
Informações da empresa
Código da empresaMXCT
Nome da EmpresaMaxCyte Inc
Data de listagemMar 29, 2016
CEOMr. Maher Masoud, J.D.
Número de funcionários114
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 29
Endereço9713 Key West Avenue,
CidadeROCKVILLE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal20850
Telefone13015175556
Sitehttps://www.maxcyte.com/
Código da empresaMXCT
Data de listagemMar 29, 2016
CEOMr. Maher Masoud, J.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
398.33K
+33.52%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
230.58K
+53.13%
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
+75.00%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
+20.58%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+136.71%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
50.00K
--
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Non-Executive Independent Director
Non-Executive Independent Director
39.89K
+86.70%
Ms. Cynthia L. Collins
Ms. Cynthia L. Collins
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William W. (Will) Brooke, J.D.
Mr. William W. (Will) Brooke, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Patrick J. Balthrop
Mr. Patrick J. Balthrop
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
398.33K
+33.52%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
230.58K
+53.13%
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
+75.00%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
+20.58%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+136.71%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
50.00K
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
Por EmpresaUSD
Nome
Receita
Proporção
Product sales
5.32M
51.16%
Licenses
4.68M
45.01%
other
397.00K
3.82%
Por RegiãoUSD
Nome
Receita
Proporção
Inside the United States
8.03M
77.32%
Outside the United States
2.36M
22.68%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Product sales
5.32M
51.16%
Licenses
4.68M
45.01%
other
397.00K
3.82%
Distribuição de ações
Atualizado em: dom, 17 de ago
Atualizado em: dom, 17 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Cadian Capital Management LP
8.36%
BlackRock Institutional Trust Company, N.A.
7.70%
Mirabella Financial Services LLP
6.19%
The Vanguard Group, Inc.
5.25%
Vitruvian Partners LLP
4.73%
Outro
67.76%
Investidores
Investidores
Proporção
Cadian Capital Management LP
8.36%
BlackRock Institutional Trust Company, N.A.
7.70%
Mirabella Financial Services LLP
6.19%
The Vanguard Group, Inc.
5.25%
Vitruvian Partners LLP
4.73%
Outro
67.76%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
24.51%
Investment Advisor
23.85%
Hedge Fund
16.40%
Private Equity
4.82%
Research Firm
4.82%
Individual Investor
1.74%
Bank and Trust
0.67%
Pension Fund
0.17%
Venture Capital
0.16%
Outro
22.84%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
296
78.80M
73.92%
-18.62M
2025Q1
308
82.56M
77.59%
-14.89M
2024Q4
308
80.42M
75.91%
-14.30M
2024Q3
300
80.65M
76.72%
-18.62M
2024Q2
297
80.25M
76.66%
-17.97M
2024Q1
302
79.09M
75.86%
-22.52M
2023Q4
303
79.97M
77.01%
-14.24M
2023Q3
292
77.05M
74.47%
-17.27M
2023Q2
284
79.82M
77.43%
-11.81M
2023Q1
275
80.19M
77.98%
-11.53M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Cadian Capital Management LP
10.03M
9.42%
+683.30K
+7.31%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.41M
6.97%
+63.83K
+0.87%
Mar 31, 2025
Mirabella Financial Services LLP
3.70M
3.48%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
5.57M
5.23%
+135.98K
+2.50%
Mar 31, 2025
Vitruvian Partners LLP
5.04M
4.74%
--
--
Mar 31, 2025
Morgan Stanley & Co. LLC
3.44M
3.23%
+3.16M
+1117.21%
Mar 31, 2025
Mudita Advisors LLP
3.33M
3.13%
+105.03K
+3.26%
Mar 31, 2025
River Global Investors LLP
3.25M
3.06%
+1.19M
+57.73%
Dec 31, 2024
Morgan Stanley Investment Management Inc. (US)
3.55M
3.34%
-547.43K
-13.36%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.58M
2.43%
+102.98K
+4.16%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: ter, 2 de set
Atualizado em: ter, 2 de set
Nome
Proporção
Invesco NASDAQ Future Gen 200 ETF
0.39%
iShares Micro-Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Biotechnology ETF
0.02%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
Ver Mais
Invesco NASDAQ Future Gen 200 ETF
Proporção0.39%
iShares Micro-Cap ETF
Proporção0.05%
Invesco Nasdaq Biotechnology ETF
Proporção0.02%
Avantis US Small Cap Equity ETF
Proporção0.02%
iShares Russell 2000 Value ETF
Proporção0.02%
ProShares Ultra Nasdaq Biotechnology
Proporção0.02%
iShares Biotechnology ETF
Proporção0.02%
Proshares Ultra Russell 2000
Proporção0.01%
iShares Russell 2000 ETF
Proporção0.01%
Global X Russell 2000 ETF
Proporção0.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
